VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at Jones Trading

Jones Trading initiated coverage on shares of VolitionRx (NYSE:VNRX - Free Report) in a research note published on Tuesday,Benzinga reports. The brokerage issued a buy rating and a $3.00 price objective on the stock.

A number of other research analysts have also recently commented on the stock. HC Wainwright initiated coverage on shares of VolitionRx in a report on Tuesday, April 8th. They issued a "buy" rating and a $2.50 price target on the stock. D. Boral Capital restated a "buy" rating and issued a $5.00 target price on shares of VolitionRx in a research note on Wednesday, April 30th. Finally, Wall Street Zen assumed coverage on shares of VolitionRx in a research report on Thursday, May 15th. They set a "sell" rating on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, VolitionRx presently has an average rating of "Hold" and an average target price of $3.50.

VolitionRx Trading Up 0.7%

Shares of VNRX stock traded up $0.00 on Tuesday, reaching $0.56. 251,532 shares of the company's stock were exchanged, compared to its average volume of 189,365. The company's fifty day simple moving average is $0.50 and its 200 day simple moving average is $0.57. VolitionRx has a 52 week low of $0.40 and a 52 week high of $0.90. The stock has a market capitalization of $57.78 million, a PE ratio of -1.56 and a beta of 1.07.

Insider Activity at VolitionRx

In other VolitionRx news, CEO Cameron John Reynolds acquired 181,818 shares of the firm's stock in a transaction dated Wednesday, March 26th. The stock was purchased at an average price of $0.55 per share, for a total transaction of $99,999.90. Following the acquisition, the chief executive officer now owns 2,299,222 shares in the company, valued at approximately $1,264,572.10. This trade represents a 8.59% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have acquired a total of 271,818 shares of company stock valued at $141,100 over the last ninety days. 10.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On VolitionRx

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Two Sigma Securities LLC purchased a new stake in VolitionRx during the 4th quarter worth approximately $29,000. Millennium Management LLC purchased a new stake in shares of VolitionRx during the fourth quarter valued at $36,000. Northern Trust Corp raised its stake in VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock worth $71,000 after acquiring an additional 28,579 shares during the last quarter. Finally, Lagoda Investment Management L.P. raised its stake in shares of VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock worth $4,546,000 after purchasing an additional 1,481,000 shares during the last quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.